ERBB2 and esophageal cancer: In this study, the tribody [(HER2)2xCD16] efficiently enhanced the cytotoxic activity of NK cells and γδ T cells of healthy persons as well as of cancer patients against HER2-expressing tumor cells including breast-, pancreatic-, ovarian-, and esophageal cancer cells.